FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891083977> ?p ?o ?g. }

• W2891083977 endingPage "e20656" @default.
• W2891083977 startingPage "e20656" @default.
• W2891083977 abstract "e20656 Background: In lung cancer the evaluation of MET, a tyrosine kinase receptor involved in tumor growth and invasiveness, for copy number amplification and point mutations is relevant for prognosis and therapy. In lung adenocarcinoma (ADC) MET amplification is observed in 1-2% and MET mutations in 3-4% of cases. Mutations mainly occur in exon 14 (ex14), which encodes for the juxtamembrane negative regulatory domain, including splice site alterations and missense mutations within the exon.Commonly, MET ex14 alterations, in particular splice site ones, are mutually exclusive with other driver mutations, but co-occurrence with MET and MDM2 amplification and KRAS mutations was described. We evaluated METex14 mutation frequency and coexistence with additional driver alterations in a prospective cohort of Italian ADC patients. Methods: 315 ADC patients were tested (January-December 2016) for MET ex14 alterations by Sanger Sequencing on formalin-fixed paraffin-embedded tissues and cytological smears (tumor cells > 40%). MET positive cases were screened also for other oncogenes, among which KRAS, BRAF and PIK3CA, using a MALDI-TOF platform, and for ROS1 translocations and MET amplification by FISH. Results: 16 patients (5%) were MET positive: 7 splice site mutations (43%) and 9 (57%) other alterations within ex14. Among splice site mutations 1 co-occurred with ROS1 translocation and 1 with MET amplification. Among other mutations we found 5 T1010I missense mutations: 3 co-occurring with G12D/G13C/Q61H KRAS, 1 with G469A BRAF and 1 with a MET intron 13 point mutation; 2 R988C mutations: 1 with G13C KRAS and 1 with G13C KRAS plus ROS1 translocation; 1 P1026S mutation and 1 frameshift deletion (p.A991del;R992fs*999), both with G12C KRAS. Conclusions: Splice site mutations cause MET activation by exon skipping and increase sensitivity to tyrosine-kinase inhibitors, whereas how other ex14 mutations affect MET function is not fully understood. In our cohort we found a high rate of METex14 mutations together with alterations in other oncogenes, mostly KRAS. The interaction of MET with cancer signaling pathways deserve further investigation in order to better define the role of ex14 mutations in the context of target therapy." @default.
• W2891083977 created "2018-09-27" @default.
• W2891083977 creator A5001928949 @default.
• W2891083977 creator A5004852923 @default.
• W2891083977 creator A5006407406 @default.
• W2891083977 creator A5015407269 @default.
• W2891083977 creator A5017086518 @default.
• W2891083977 creator A5017474339 @default.
• W2891083977 creator A5029495871 @default.
• W2891083977 creator A5052697026 @default.
• W2891083977 creator A5053165703 @default.
• W2891083977 creator A5053998173 @default.
• W2891083977 creator A5062859034 @default.
• W2891083977 creator A5063424146 @default.
• W2891083977 creator A5068503607 @default.
• W2891083977 creator A5071783009 @default.
• W2891083977 creator A5079703596 @default.
• W2891083977 creator A5084432192 @default.
• W2891083977 creator A5088595075 @default.
• W2891083977 creator A5091906718 @default.
• W2891083977 date "2017-05-20" @default.
• W2891083977 modified "2023-10-16" @default.
• W2891083977 title "MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations." @default.
• W2891083977 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20656" @default.
• W2891083977 hasPublicationYear "2017" @default.
• W2891083977 type Work @default.
• W2891083977 sameAs 2891083977 @default.
• W2891083977 citedByCount "1" @default.
• W2891083977 countsByYear W28910839772020 @default.
• W2891083977 crossrefType "journal-article" @default.
• W2891083977 hasAuthorship W2891083977A5001928949 @default.
• W2891083977 hasAuthorship W2891083977A5004852923 @default.
• W2891083977 hasAuthorship W2891083977A5006407406 @default.
• W2891083977 hasAuthorship W2891083977A5015407269 @default.
• W2891083977 hasAuthorship W2891083977A5017086518 @default.
• W2891083977 hasAuthorship W2891083977A5017474339 @default.
• W2891083977 hasAuthorship W2891083977A5029495871 @default.
• W2891083977 hasAuthorship W2891083977A5052697026 @default.
• W2891083977 hasAuthorship W2891083977A5053165703 @default.
• W2891083977 hasAuthorship W2891083977A5053998173 @default.
• W2891083977 hasAuthorship W2891083977A5062859034 @default.
• W2891083977 hasAuthorship W2891083977A5063424146 @default.
• W2891083977 hasAuthorship W2891083977A5068503607 @default.
• W2891083977 hasAuthorship W2891083977A5071783009 @default.
• W2891083977 hasAuthorship W2891083977A5079703596 @default.
• W2891083977 hasAuthorship W2891083977A5084432192 @default.
• W2891083977 hasAuthorship W2891083977A5088595075 @default.
• W2891083977 hasAuthorship W2891083977A5091906718 @default.
• W2891083977 hasConcept C104317684 @default.
• W2891083977 hasConcept C121608353 @default.
• W2891083977 hasConcept C142724271 @default.
• W2891083977 hasConcept C153911025 @default.
• W2891083977 hasConcept C176944494 @default.
• W2891083977 hasConcept C194583182 @default.
• W2891083977 hasConcept C21790070 @default.
• W2891083977 hasConcept C2775999482 @default.
• W2891083977 hasConcept C2776232967 @default.
• W2891083977 hasConcept C2776256026 @default.
• W2891083977 hasConcept C2779422266 @default.
• W2891083977 hasConcept C2780989783 @default.
• W2891083977 hasConcept C2781182431 @default.
• W2891083977 hasConcept C2781187634 @default.
• W2891083977 hasConcept C36823959 @default.
• W2891083977 hasConcept C501734568 @default.
• W2891083977 hasConcept C502942594 @default.
• W2891083977 hasConcept C54355233 @default.
• W2891083977 hasConcept C62257209 @default.
• W2891083977 hasConcept C71924100 @default.
• W2891083977 hasConcept C75563809 @default.
• W2891083977 hasConcept C76818968 @default.
• W2891083977 hasConcept C86803240 @default.
• W2891083977 hasConceptScore W2891083977C104317684 @default.
• W2891083977 hasConceptScore W2891083977C121608353 @default.
• W2891083977 hasConceptScore W2891083977C142724271 @default.
• W2891083977 hasConceptScore W2891083977C153911025 @default.
• W2891083977 hasConceptScore W2891083977C176944494 @default.
• W2891083977 hasConceptScore W2891083977C194583182 @default.
• W2891083977 hasConceptScore W2891083977C21790070 @default.
• W2891083977 hasConceptScore W2891083977C2775999482 @default.
• W2891083977 hasConceptScore W2891083977C2776232967 @default.
• W2891083977 hasConceptScore W2891083977C2776256026 @default.
• W2891083977 hasConceptScore W2891083977C2779422266 @default.
• W2891083977 hasConceptScore W2891083977C2780989783 @default.
• W2891083977 hasConceptScore W2891083977C2781182431 @default.
• W2891083977 hasConceptScore W2891083977C2781187634 @default.
• W2891083977 hasConceptScore W2891083977C36823959 @default.
• W2891083977 hasConceptScore W2891083977C501734568 @default.
• W2891083977 hasConceptScore W2891083977C502942594 @default.
• W2891083977 hasConceptScore W2891083977C54355233 @default.
• W2891083977 hasConceptScore W2891083977C62257209 @default.
• W2891083977 hasConceptScore W2891083977C71924100 @default.
• W2891083977 hasConceptScore W2891083977C75563809 @default.
• W2891083977 hasConceptScore W2891083977C76818968 @default.
• W2891083977 hasConceptScore W2891083977C86803240 @default.
• W2891083977 hasIssue "15_suppl" @default.
• W2891083977 hasLocation W28910839771 @default.
• W2891083977 hasOpenAccess W2891083977 @default.
• W2891083977 hasPrimaryLocation W28910839771 @default.

• next